TGTX•benzinga•
TG Therapeutics Raising FY24 BRIUMVI US Net Product Revenue Target To $300M - $305M From Prior Guidance Of $290M - $300M
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 4, 2024 by benzinga